Illumina, Inc. (ILMN) News

Illumina, Inc. (ILMN): $453.17

2.50 (+0.55%)

POWR Rating

Component Grades













Add ILMN to Watchlist
Sign Up

Industry: Biotech


of 487

in industry

Filter ILMN News Items

ILMN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ILMN News Highlights

  • 500 - Internal server error
  • Over the past 25 days, the trend for ILMN's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • The most mentioned tickers in articles about ILMN are GENE, PACB and BDX.

Latest ILMN News From Around the Web

Below are the latest news stories about Illumina Inc that investors may wish to consider to help them evaluate ILMN as an investment opportunity.

5 Healthcare Stocks to Buy for Their Game-Changing Potential

These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies.

Larry Ramer on InvestorPlace | June 8, 2021

7 Beaten-Down Stocks to Buy Right Now for a June Rebound

Are you looking for stocks that have been beaten up in recent weeks?

Tezcan Gecgil on InvestorPlace | June 7, 2021

Illumina rises as GRAIL presents data from early cancer detection test

Photo by Georgejason/iStock Editorial via Getty Images Illumina ([[ILMN]] +3.7%) is soaring in reaction to the data announced by the cancer startup GRAIL for Galleri, a multi-cancer early detection ((MCED)) blood test. Illumina has signed an agreement to acquire GRAIL in a deal valued at $7.1B. The first results from...

Seeking Alpha | June 4, 2021

This Biotech Just Made History. Will Its Stock Follow?

About 8% of our genetic instructions remained untouched even after the sequencing project officially ended. The accomplishment is thanks in large part to new sequencing technology from Pacific Biosciences of California (NASDAQ: PACB). The initial project relied on sequencers like those made by Illumina (NASDAQ: ILMN), which reassemble short fragments of DNA after cutting them up and decoding them.

Yahoo | June 4, 2021

Grail Will Begin Selling Its Multi-Cancer Blood Test. It Could Be the Start of a Huge Market.

The private cancer testing firm Grail said early Friday that it had begun selling its multi-cancer blood test in the U.S.

Yahoo | June 4, 2021

2 Winners for a Drug Development Future That Looks Nothing Like the Past

In hindsight, the pandemic may have been that turning point for gene-based medicine. The authorization of the first vaccines using messenger RNA validated a segment of the life sciences industry that seemed destined for some futuristic version of healthcare. Genome sequencing and gene editing have been around for several years.

Yahoo | June 4, 2021

Strong seasonal pattern for Illumina (ILMN Stock) [Video]

The broad conditions for equity buyers remain in place. Easy central bank monetary policy and broad fiscal stimulus mean conditions are suitable for f

FXStreet | June 3, 2021

Expert Ratings for Illumina

Illumina (NASDAQ: ILMN ) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months…

Business Insider Markets | June 1, 2021

Illumina (ILMN) Expands NIPT Offering With New Collaboration

Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.

Yahoo | June 1, 2021

Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis

Illumina and BeSolveRD will study the clinical utility and health economic impact of WGS of patients with intellectual disabilities.

Yahoo | June 1, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5407 seconds.